Antibody Approach To CGRP Offers Safer Mode For Migraine Prevention, Labrys Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Labrys is ready to advance a monoclonal antibody to Phase II for prevention of chronic migraine, after releasing pooled safety from five Phase I trials conducted by Pfizer.